Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Clinical trial NCT05602415 · UNKNOWN

Trial details

NCT number: NCT05602415
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Soft Tissue Sarcoma High Risk of Recurrence Anlotinib Radiotherapy

Start date: 2022-11-01
Primary completion: 2023-01-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.